You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

XURIDEN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Xuriden patents expire, and what generic alternatives are available?

Xuriden is a drug marketed by Btg Intl and is included in one NDA.

The generic ingredient in XURIDEN is uridine triacetate. There are thirty-six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the uridine triacetate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for XURIDEN?
  • What are the global sales for XURIDEN?
  • What is Average Wholesale Price for XURIDEN?
Summary for XURIDEN
Drug patent expirations by year for XURIDEN
Drug Prices for XURIDEN

See drug prices for XURIDEN

Pharmacology for XURIDEN

US Patents and Regulatory Information for XURIDEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Btg Intl XURIDEN uridine triacetate GRANULE;ORAL 208169-001 Sep 4, 2015 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for XURIDEN

See the table below for patents covering XURIDEN around the world.

Country Patent Number Title Estimated Expiration
Russian Federation 2203669 СПОСОБЫ ЛЕЧЕНИЯ СЕПСИСА И ВОСПАЛЕНИЙ С ПОМОЩЬЮ ОКСИПУРИНОВЫХ НУКЛЕОЗИДОВ (METHOD FOR TREATING SEPSIS AND INFLAMMATIONS DUE TO OXYPURINE NUCLEOSIDES) ⤷  Sign Up
Spain 2160579 ⤷  Sign Up
Japan 2003160585 OXYPURINE NUCLEOSIDE FOR IMPROVEMENT OF HEMATOPOIESIS, ITS HOMOLOG AND ITS ACRYL DERIVATIVE ⤷  Sign Up
Germany 69635941 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for XURIDEN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2207786 2023C/550 Belgium ⤷  Sign Up PRODUCT NAME: CEDAZURIDINE, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1756 20230918
2207786 2023C/551 Belgium ⤷  Sign Up PRODUCT NAME: UNE COMPOSITION COMPRENANT : DE LA CEDAZURIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ; ET LA DECITABINE; AUTHORISATION NUMBER AND DATE: EU/1/23/1756 20230918
1849470 2017/033 Ireland ⤷  Sign Up PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160425
1849470 300889 Netherlands ⤷  Sign Up PRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.